EGFR and non-small cell lung carcinoma: The ADJUVANT/CTONG1104 study compared gefitinib with cisplatin/vinorelbine (cis/vin) for stage II–III EGFR‐mutated NSCLC and showed a significant prolongation of DFS by gefitinib (hazard ratio [HR] 0.56, P = 0.001) but not OS [10, 11].